Today: 7 February 2026
Subscribe
Browse Category

Investment Analysis News 20 December 2025

Intuit (INTU) Stock News, Forecasts and Analyst Outlook: USDC Stablecoin Deal, TurboTax 2026 Tax Push, and Key Catalysts (Dec. 20, 2025)

Intuit (INTU) Stock News, Forecasts and Analyst Outlook: USDC Stablecoin Deal, TurboTax 2026 Tax Push, and Key Catalysts (Dec. 20, 2025)

Dec. 20, 2025 — Intuit Inc. (NASDAQ: INTU) enters the weekend with investors balancing a fresh fintech headline—Intuit’s newly announced USDC stablecoin partnership with Circle—against the familiar seasonal catalyst that often defines the stock’s narrative: TurboTax demand heading into the 2026 filing season (tax year 2025 returns filed in early 2026). Intuit Inc.+1 With U.S. markets closed on Saturday, the latest available pricing reflects Friday’s session: INTU closed at $671.30 on Dec. 19, capping a choppy week that saw the stock dip early and rebound into the close. StockAnalysis Below is a comprehensive, publication-ready breakdown of the latest INTU stock
20 December 2025
····
IBM Stock News and Forecast for 2026: IBM Shares Hold Near $301 as Confluent Deal, Credit Outlook, and Analyst Calls Collide (Dec. 20, 2025)

IBM Stock News and Forecast for 2026: IBM Shares Hold Near $301 as Confluent Deal, Credit Outlook, and Analyst Calls Collide (Dec. 20, 2025)

International Business Machines Corporation (NYSE: IBM) enters the final stretch of 2025 with its stock consolidating near the $300 level—an area that has become a focal point for both bulls betting on IBM’s “AI + hybrid cloud” strategy and skeptics warning that the company’s acquisition push could strain the balance sheet. IBM stock last closed at $300.98 on Friday, Dec. 19, 2025, up about 0.18% on the day. With U.S. markets closed on Saturday, Dec. 20, that close is the latest reference point for investors tracking the name into year-end. StockAnalysis What’s driving the debate right now is a tight
20 December 2025
·····
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets

December 20, 2025 — Insmed Incorporated (NASDAQ: INSM) is ending the week in “re-pricing mode” after a mid-stage clinical setback jolted investor expectations, sparked sharp volatility, and triggered a round of analyst price-target revisions. By Friday’s close (the last U.S. trading session before today’s Saturday), Insmed shares finished at $174.84, up about 5% on the day—recovering some ground after Thursday’s steep drop. The catalyst remains the same: Insmed disclosed that its Phase 2b BiRCh study of brensocatib (brand: Brinsupri) in chronic rhinosinusitis without nasal polyps (CRSsNP)missed both primary and secondary efficacy endpoints, prompting the company to discontinue that indication. At
20 December 2025
····
Texas Instruments Stock (NASDAQ: TXN) on Dec. 20, 2025: Sherman Fab Starts Production, Analysts Split on the 2026 Outlook

Texas Instruments Stock (NASDAQ: TXN) on Dec. 20, 2025: Sherman Fab Starts Production, Analysts Split on the 2026 Outlook

December 20, 2025 Texas Instruments Incorporated (NASDAQ: TXN) heads into the weekend at the center of two narratives that rarely collide so neatly: a major U.S. manufacturing milestone and a fresh wave of Wall Street debate about what that investment means for margins, cash flow, and share performance in the next semiconductor cycle. TXN last closed at $176.29 (Dec. 19, 2025), with trading in recent sessions reflecting investor tug-of-war between long-term capacity advantages and short-term profitability concerns. StockAnalysis Below is a full roundup of the current news, forecasts, and analyses relevant to Texas Instruments stock as of 20.12.2025, plus the
20 December 2025
·····
Goldman Sachs Stock (NYSE: GS): Latest News, Analyst Forecasts, and 2026 Outlook as of December 20, 2025

Goldman Sachs Stock (NYSE: GS): Latest News, Analyst Forecasts, and 2026 Outlook as of December 20, 2025

NEW YORK — December 20, 2025 — Goldman Sachs Group, Inc. (NYSE: GS) is closing out 2025 with momentum: a strong year for big banks, a revived deal pipeline, and fresh headlines that reinforce the firm’s push deeper into AI-driven infrastructure, software dealmaking, and active ETFs. But with GS trading near its highs, the stock debate is shifting from “recovery” to “valuation and sustainability.” Below is a comprehensive roundup of the most relevant GS stock news, forecasts, and market analysis available as of 20.12.2025, plus what investors are watching next. Goldman Sachs stock price today: where GS stands heading into
20 December 2025
·····
AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

December 20, 2025 — AbbVie Inc. (NYSE: ABBV) is closing out the week in the spotlight as U.S. drug-pricing policy headlines collide with a still-strong “post-Humira” growth narrative built around Skyrizi and Rinvoq. The stock finished the last regular session (Friday, Dec. 19) at $226.82, up 1.80%, while trading volume surged well above its recent average — a sign that investors were repositioning into large-cap pharma after a rapid sequence of Washington announcements. MarketWatch Below is a full roundup of what’s driving AbbVie stock right now (as of 20.12.2025), what analysts are forecasting, and which catalysts could matter most heading
20 December 2025
·····
Data Center Stocks: AI Capex Boom Meets Power-Grid Bottlenecks — Today’s News and 2026 Outlook (Dec. 20, 2025)

Data Center Stocks: AI Capex Boom Meets Power-Grid Bottlenecks — Today’s News and 2026 Outlook (Dec. 20, 2025)

December 20, 2025 — Data center stocks have become one of the market’s most crowded (and consequential) intersections: artificial intelligence demand on one side, and real-world constraints—power, land, permitting, and financing—on the other. The investment story isn’t just about more GPUs and bigger server halls. It’s increasingly about who can secure megawatts, finance the build, and turn capex into durable cash flow. This weekend’s headlines sharpen that tension. Regulators in Georgia approved a massive electricity-generation expansion to serve data centers. In the Mid-Atlantic, federal regulators pushed PJM to clarify rules for AI-driven large loads—especially when they’re colocated near power plants.
20 December 2025
··········
Rare Metals Stocks: Rare Earth Magnet Exports Rebound, Gallium Deals Grow, and Lithium Signals Turn Sharper (Dec. 20, 2025)

Rare Metals Stocks: Rare Earth Magnet Exports Rebound, Gallium Deals Grow, and Lithium Signals Turn Sharper (Dec. 20, 2025)

Rare metals stocks are ending 2025 with a familiar mix of geopolitics, supply-chain data, and fast-moving technology shifts—only now, the market is increasingly treating “rare metals” as a policy asset class, not just a commodity trade. On December 20, 2025, the clearest signal came from the rare earths corner of the market: China’s rare-earth magnet exports climbed to their second-highest level on record in November, suggesting a partial normalization of shipments after months of licensing friction. At the same time, new “general” export licences and fresh Western processing initiatives are reshaping the long-term investment case for rare earth stocks and
20 December 2025
·····
Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

As of Saturday, December 20, 2025, investors are digesting a busy stretch of developments around Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)—from Nasdaq-100 index inclusion (effective Dec. 22) to fresh reimbursement tailwinds in the U.K. and continued focus on Amvuttra (vutrisiran) as the company’s main growth engine. Nasdaq+1 Below is a comprehensive roundup of the latest ALNY stock news, forecasts, and market-moving analysis available as of 20.12.2025, plus what to watch next. ALNY stock today: where Alnylam shares stand on Dec. 20, 2025 U.S. markets are closed on Saturday, so the most recent official pricing is from Friday’s session (Dec. 19, 2025).
20 December 2025
·····
Qualcomm Stock (QCOM) News, Forecasts and Analysis for December 20, 2025: Alphawave Semi Deal, Insider Sales, and the 2026 Outlook

Qualcomm Stock (QCOM) News, Forecasts and Analysis for December 20, 2025: Alphawave Semi Deal, Insider Sales, and the 2026 Outlook

December 20, 2025 — With U.S. markets closed for the weekend, the latest read on QUALCOMM Incorporated (NASDAQ: QCOM) comes from Friday’s session: QCOM last closed at $175.25 and traded modestly higher in after-hours. StockAnalysis That price point sits at an interesting intersection for investors: Qualcomm is finishing 2025 with a stronger-than-usual run, expanding its “beyond smartphones” narrative, and stacking near-term catalysts (including a major acquisition and the next earnings cycle) against a valuation that commentators argue has become far less forgiving. Below is a comprehensive roundup of the most current Qualcomm stock news, forecasts, and market analysis available as
20 December 2025
·····
Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

December 20, 2025 — Amgen Inc. (NASDAQ: AMGN) is closing out the year with a rare combination of near-term policy headlines and company-specific catalysts that matter to investors: a new U.S. drug-pricing deal tied to the TrumpRx rollout, fresh FDA approvals that expand the growth runway, reaffirmed shareholder returns via dividends, and a split—but active—Wall Street outlook heading into 2026. AMGN last traded around $327.38, reflecting the most recent available market print (U.S. markets are closed today). Below is a detailed, publication-ready breakdown of today’s key Amgen stock news, along with forecasts and analyst analysis relevant as of 20.12.2025. What’s
20 December 2025
·····
Salesforce (CRM) Stock News and Forecasts on Dec. 20, 2025: Agentforce AI Momentum, Qualified Acquisition, and Wall Street Price Targets

Salesforce (CRM) Stock News and Forecasts on Dec. 20, 2025: Agentforce AI Momentum, Qualified Acquisition, and Wall Street Price Targets

December 20, 2025 — Salesforce, Inc. (NYSE: CRM) stock is heading into the final stretch of 2025 at the center of a debate investors know well: is this a beaten-down software leader becoming a bargain again, or a “value trap” in a market that’s rewarding AI infrastructure over traditional SaaS? MarketWatch On price action, Salesforce shares last traded around $259.91, after closing Friday, Dec. 19, 2025 at $259.91, up 0.80% on the day, with roughly 20.7 million shares traded. Investing.com What’s driving attention this weekend isn’t a single headline—it’s the convergence of AI commercialization, fresh M&A, and renewed analyst conviction
20 December 2025
·····
1 … 124 125 126 127 128 … 282

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
Go toTop